Uptake kinetics of 99mTc-MAG3-antisense oligonucleotide to PCNA and effect on gene expression in vascular smooth muscle cells

Journal of Nuclear Medicine

Volumn 46, Issue 6, 2005, Pages 1052-1058

  Zhang, Yan Rong ^a   Zhang, Yong Xue ^a,b   Cao, Wei ^a   Lan, Xiao Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NONE   (China)

Author keywords

Antisense oligonucleotide; Atherosclerotic plaque; Proliferating cell nucleus antigen; Restenosis; Vascular smooth muscle cells

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLINE; DNA; MERTIATIDE TC 99M; MESSENGER RNA; SEPHADEX; ANTISENSE OLIGONUCLEOTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG STABILITY; DRUG UPTAKE; GENE EXPRESSION; HYBRIDIZATION; IN VITRO STUDY; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RADIOCHEMISTRY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DOWN REGULATION; GENETICS; METABOLISM; RADIATION EXPOSURE; SPRAGUE DAWLEY RAT;

ANIMALS; CELLS, CULTURED; DOWN-REGULATION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OLIGONUCLEOTIDES, ANTISENSE; PROLIFERATING CELL NUCLEAR ANTIGEN; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TECHNETIUM TC 99M MERTIATIDE;

EID: 23044509685     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci. 1973;75:230-234.
2. Abaza MS, Al-Attiyah RJ, Al-Saffar AM, et al. Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells. Tumour Biol. 2003;24:241-257.
3. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta. 1999;1439:31-44.
4. Joshi PJ, Fisher TS, Prasad VR. Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr Drug Targets Infect Disord. 2003;3:333-400.
5. Clawson GA, Miranda GQ, Sivarajah A, et al. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA. Gene Ther. 2004;11:1331-1341.
6. Fukuda N, Furuya R, Kishioka H, et al. Effects of antisense peptide nucleic acid to platelet-derived growth factor A-chain on growth of vascular smooth muscle cells. J Cardiovasc Pharmacol. 2003;42:224-231.
7. Suzuki J, Isobe M, Monshita R, et al. Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts. Cardiovasc Res. 2000;45:783-787.
8. Suzuki J, Isobe M, Morishita R, et al. Prevention of cardiac allograft arteriosclerosis using antisense proliferating-cell nuclear antigen oligonucleotide. Transplantation. 2000;70:398-400.
9. Kipshidze NN, Kim HS, Iversen P, et al. Intramural coronary delivery of advanced antisense ohgonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol. 2002;39:1686-1691.
10. Freedman SB. Clinical trials of gene therapy for atherosclerotic cardiovascular disease. Curr Opin Lipidol. 2002;13:653-661.
11. Hudziak RM, Summerton J, Weller DD, et al. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. 2000;10:163-176.
12. 68Ga-labeled ohgonucleotides for in vivo imaging with PET. J Natl Med. 2004;45:347-355.
13. Tavitian B. In vivo imaging with oligonucleotides for diagnosis and drug development. Gut. 2003;52:iv40-iv47.
14. Tian X, Aruva MR, Rao PS, et al. Imaging oncogene expression. Ann N Y Acad Sci. 2003;1002:165-188.
15. Gallazzi F, Wang Y, Jia F, et al. Synthesis of radiometal-labeled and fluorescent cell-permeating peptide-PNA conjugates for targeting the bcl-2 proto-oncogene. Bioconjug Chem. 2003;14:1083-1095.
16. McCaffrey AP, Meuse L, Karimi M, et al. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology. 2003;38:503-508.
17. 99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNA in tumors. Nucl Med Commun. 2003;24:857-863.
18. Qin G, Zhang Y, Cao W, et al. Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides. Eur J Nucl Med Mol Imaging. 2005;32:6-14.
19. 3 for technetium-99m labeling of DNA. Nucl Med Biol. 1997;24:425-432.
20. 3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med. 2000;72:1700-1707.
21. Lawson C, Ainsworth ME, McCormack AM, et al. Effects of cross-linking ICAM-1 on the surface of human vascular smooth muscle cells: induction of VCAM-1 but no proliferation. Cardiovasc Res. 2001;50:547-555.
22. Selkirk SM. Gene therapy in clinical medicine. Postgrad Med J. 2004;80:560-570.
23. Dinsmore R. Imaging techniques in carotid and peripheral vascular disease. In: Fuster V, ed. Syndromes of Atherosclerosis Correlations of Clinical Imaging and Pathology. Armonk, NY: Futura Publishing Co., Inc.; 1996:277-289.
24. von Birgelen C, Slager CJ, Di Mario C, et al. Volumetric intracoronary ultrasound: a new maximum confidence approach for the quantitative assessment of progression-regression of atherosclerosis? Atherosclerosis. 1995;118:S103-S113.
25. den Heijer P, Foley DP, Hillege HU et al. The "Ermenonville" classification of observations at coronary angioscopy: evaluation of intra- and inter-observer agreement-European Working Group on Coronary Angioscopy. Eur Heart J. 1994;15:815-822.
26. Iuliano L, Signore A, Vallabajosula S, et al. Preparation and biodistribution of 99m-technetium labelled oxidized LDL in man. Atherosclerosis. 1996;126:131-141.
27. Tsimikas S, Palinski W, Halpem SE, et al. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol. 1999;6:41-53.
28. 123labeled synthetic peptide fragment. J Clin Pharmacol. 1993;33:1039-1047.
29. Carrio I, Pieri PL, Narula J, et al. Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. J Nucl Cardiol. 1998;5:551-557.
30. Stratton JR, Dewhurst TA, Kasina S, et al. Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation. 1995;92:3113-3121.
31. 18F-FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32:70-76.
32. 15F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-2711.
33. Lavezzi AM, Milei J, Grana DR, et al. Expression of c-fos, p53 and PCNA in the unstable atherosclerotic carotid plaque. Int J Cardiol. 2003;92:59-63.
34. Wei GL, Krasinski K, Keamey M, et al. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418-426.
35. Ihling C, Technau K, Gross V, et al. Concordant upregulation of type II-TGF-beta-receptor, the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity. Atherosclerosis. 1999;144:7-14.
36. Shen LJ, Zhang HX, Zhang ZJ, et al. Detection of HBV, PCNA and GST-pi in hepatocellular carcinoma and chronic liver disease. World J Gastroenterol. 2003;9:459-462.
37. Shang S, Takai N, Nishida M, et al. CaMKIV expression is associated with clinical stage and PCNA-labeling index in endometrial carcinoma. Int J Mol Med. 2003;11:181-186.
38. Jorge O, Parasi AS, Manioudaki HS, et al. Prognostic impact of DNA ploidy pattern, S-phage fraction (SPF), and proliferating cell nuclear antigene (PCNA) in patients with primary gastric lymphoma. J Surg Oncol. 2003;82:247-255.
39. Kushlinskii NE, Orinovskii ME, Gurevich LE, et al. Expression of biomolecular markers (Ki-67, PCNA, Bcl-2, BAX, BclX, VEGF) in breast tumors. Bull Exp Biol Med. 2004;137:132-135.
40. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation. 1992;86:538-547.